AstraZeneca (LON:AZN) Share Price Crosses Above 200-Day Moving Average – Here’s What Happened

Shares of AstraZeneca PLC (LON:AZN) crossed above its two hundred day moving average during trading on Friday . The stock has a two hundred day moving average of £141.38 and traded as high as £145.66. AstraZeneca shares last traded at £144.56, with a volume of 649,606 shares changing hands.

Analysts Set New Price Targets

Several brokerages recently weighed in on AZN. Citigroup increased their price objective on AstraZeneca from £170 to £180 and gave the stock a “buy” rating in a research report on Friday, April 10th. Deutsche Bank Aktiengesellschaft restated a “sell” rating and issued a £115 target price on shares of AstraZeneca in a research report on Friday, June 26th. Finally, Jefferies Financial Group reaffirmed a “buy” rating and issued a £180 price target on shares of AstraZeneca in a research note on Friday, June 26th. Five equities research analysts have rated the stock with a Buy rating and one has given a Sell rating to the stock. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of £153.33.

AstraZeneca Stock Down 0.6%

The business’s 50 day moving average price is £137.36 and its 200-day moving average price is £141.38. The company has a debt-to-equity ratio of 71.66, a quick ratio of 0.59 and a current ratio of 0.91. The firm has a market capitalization of £224.19 billion, a PE ratio of 21.77, a P/E/G ratio of 0.86 and a beta of 0.21.

AstraZeneca Company Profile

AstraZeneca (LSE/STO/Nasdaq: AZN) is a global, science-led biopharmaceutical company that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of diseases in three therapy areas – Oncology, Cardiovascular, Renal & Metabolism, and Respiratory & Immunology.
Based in Cambridge, UK, AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide. Please visit astrazeneca.com and follow the Company on Twitter @AstraZeneca.